Form 4: Catalyst Pharma Director Boosts Equity Holdings

Catalyst Pharmaceuticals Director Tamar Thompson reported significant equity awards, including new options and restricted stock units, alongside the vesting of existing RSUs.

Summary

• Tamar Thompson, a Director at Catalyst Pharmaceuticals, Inc. (CPRX), reported transactions involving the company's equity securities.
• On November 20, 2025, Thompson was granted 18,115 options to purchase common stock at an exercise price of $22.77, expiring on November 20, 2032.
• These options vest in three equal tranches on November 20, 2026, November 20, 2027, and November 20, 2028.
• Thompson also received a grant of 5,468 Restricted Stock Units (RSUs) on November 20, 2025, which vest in three equal tranches on November 20, 2026, November 20, 2027, and November 20, 2028.
• On November 21, 2025, 947 RSUs vested and were converted into 947 shares of common stock, which were delivered to Thompson.
• Additionally, 947 new Restricted Stock Units were granted on November 21, 2025, with vesting in three equal tranches on November 21, 2025, November 21, 2026, and November 21, 2027.
• Following these transactions, Thompson directly beneficially owns 2,360 shares of common stock.
• Thompson's total beneficial ownership of derivative securities includes 116,555 options and 121,076 Restricted Stock Units.

Sentiment

Score: 7

Explanation: The filing indicates a director's increased equity exposure through new grants and vesting, which is generally viewed positively as it aligns management's interests with shareholders and signals confidence in the company's future.

Positives

• The significant grant of 18,115 stock options and 5,468 restricted stock units to a director aligns management's interests with long-term shareholder value.
• The vesting and delivery of 947 shares from previously granted restricted stock units demonstrate the realization of equity compensation and increased direct ownership by a director.
• Increased insider ownership generally signals confidence in the company's future prospects.

Industry Context

In the pharmaceutical and biotechnology industry, equity compensation, such as stock options and restricted stock units, is a standard practice for attracting, retaining, and incentivizing directors and executives. These grants are designed to align the interests of company leadership with the long-term performance and shareholder value of the company, a common strategy across the sector.

Comparison to Industry Standards

• The equity compensation package, including stock options and restricted stock units with multi-year vesting schedules, is consistent with typical director compensation structures observed in publicly traded pharmaceutical and biotech companies of similar market capitalization and stage of development.

Stakeholder Impact

• Shareholders: Increased alignment of a director's financial interests with long-term shareholder value due to significant equity grants and holdings.
• Employees: May signal stability and confidence in the company's leadership and strategic direction.

Next Steps

• Future vesting of 18,115 stock options in tranches on November 20, 2026, November 20, 2027, and November 20, 2028.
• Future vesting of 5,468 restricted stock units in tranches on November 20, 2026, November 20, 2027, and November 20, 2028.
• Future vesting of 947 restricted stock units in tranches on November 21, 2026, and November 21, 2027.

Key Dates

Keywords

Catalyst Pharmaceuticals, CPRX, Form 4, Insider Transaction, Stock Options, Restricted Stock Units, Director Compensation, Equity Grant, Beneficial Ownership